| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adipose tissue and breast cancer progression: A link between metabolism and cancer
|
Bertolini, Francesco
|
|
2013
|
22 |
S2 |
p. S48-S49
2 p.
|
artikel
|
| 2 |
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer
|
Fu, Xiaoyong
|
|
2013
|
22 |
S2 |
p. S12-S18
7 p.
|
artikel
|
| 3 |
Breast cancer screening: Controversy of impact
|
Berry, Donald A.
|
|
2013
|
22 |
S2 |
p. S73-S76
4 p.
|
artikel
|
| 4 |
Characterization and clinical impact of residual disease after neoadjuvant chemotherapy
|
Viale, Giuseppe
|
|
2013
|
22 |
S2 |
p. S88-S91
4 p.
|
artikel
|
| 5 |
Close/positive margins after breast-conserving therapy: Additional resection or no resection?
|
Wood, William C.
|
|
2013
|
22 |
S2 |
p. S115-S117
3 p.
|
artikel
|
| 6 |
Developing an effective breast cancer vaccine: Challenges to achieving sterile immunity versus resetting equilibrium
|
Curigliano, Giuseppe
|
|
2013
|
22 |
S2 |
p. S96-S99
4 p.
|
artikel
|
| 7 |
Expert opinion vs guideline based care: The St. Gallen Case study
|
Burstein, Harold
|
|
2013
|
22 |
S2 |
p. S1-S2
2 p.
|
artikel
|
| 8 |
Extended adjuvant chemotherapy in endocrine non-responsive disease
|
Colleoni, Marco
|
|
2013
|
22 |
S2 |
p. S161-S164
4 p.
|
artikel
|
| 9 |
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer
|
Strasser-Weippl, Kathrin
|
|
2013
|
22 |
S2 |
p. S171-S175
5 p.
|
artikel
|
| 10 |
Extracellular matrix components in breast cancer progression and metastasis
|
Oskarsson, Thordur
|
|
2013
|
22 |
S2 |
p. S66-S72
7 p.
|
artikel
|
| 11 |
Follow-up tests to detect recurrent disease: Patient's reassurance or medical need?
|
Smith, Ian E.
|
|
2013
|
22 |
S2 |
p. S156-S160
5 p.
|
artikel
|
| 12 |
From genome to bedside: Are we lost in translation?
|
Hayes, Daniel F.
|
|
2013
|
22 |
S2 |
p. S22-S26
5 p.
|
artikel
|
| 13 |
Hypofractionation in the era of modulated radiotherapy (RT)
|
Mouw, Kent W.
|
|
2013
|
22 |
S2 |
p. S129-S136
8 p.
|
artikel
|
| 14 |
Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer
|
Abu-Khalaf, Maysa
|
|
2013
|
22 |
S2 |
p. S83-S87
5 p.
|
artikel
|
| 15 |
Is regional nodes radiotherapy an alternative to surgery?
|
Offersen, Birgitte Vrou
|
|
2013
|
22 |
S2 |
p. S118-S128
11 p.
|
artikel
|
| 16 |
Magnetic resonance imaging: The evolution of breast imaging
|
Heywang-Köbrunner, Sylvia H.
|
|
2013
|
22 |
S2 |
p. S77-S82
6 p.
|
artikel
|
| 17 |
Management of breast cancer in very young women
|
Freedman, Rachel A.
|
|
2013
|
22 |
S2 |
p. S176-S179
4 p.
|
artikel
|
| 18 |
Mutational analysis of breast cancer: Guiding personalized treatments
|
Ellis, Matthew J.
|
|
2013
|
22 |
S2 |
p. S19-S21
3 p.
|
artikel
|
| 19 |
Nutrition and physical activity influence on breast cancer incidence and outcome
|
Chlebowski, Rowan T.
|
|
2013
|
22 |
S2 |
p. S30-S37
8 p.
|
artikel
|
| 20 |
Obesity and endocrine therapy: Host factors and breast cancer outcome
|
Goodwin, Pamela J.
|
|
2013
|
22 |
S2 |
p. S44-S47
4 p.
|
artikel
|
| 21 |
Oncoplastic and reconstructive surgery of the breast
|
Hamdi, Moustapha
|
|
2013
|
22 |
S2 |
p. S100-S105
6 p.
|
artikel
|
| 22 |
Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer
|
Jankowitz, Rachel C.
|
|
2013
|
22 |
S2 |
p. S165-S170
6 p.
|
artikel
|
| 23 |
Partial breast irradiation: Targeting volume or breast molecular subtypes?
|
Orecchia, Roberto
|
|
2013
|
22 |
S2 |
p. S137-S140
4 p.
|
artikel
|
| 24 |
Partial breast re-irradiation for local recurrence of breast carcinoma: Benefit and long term side effects
|
Sedlmayer, Felix
|
|
2013
|
22 |
S2 |
p. S141-S146
6 p.
|
artikel
|
| 25 |
Patients with triple negative breast cancer: Is there an optimal adjuvant treatment?
|
Burstein, Harold J.
|
|
2013
|
22 |
S2 |
p. S147-S148
2 p.
|
artikel
|
| 26 |
Personalized adjuvant therapies: Lessons from the past
|
Goldhirsch, Aron
|
|
2013
|
22 |
S2 |
p. S3-S7
5 p.
|
artikel
|
| 27 |
Personalizing extent of breast cancer surgery according to molecular subtypes
|
Morrow, Monica
|
|
2013
|
22 |
S2 |
p. S106-S109
4 p.
|
artikel
|
| 28 |
p53 in breast cancer subtypes and new insights into response to chemotherapy
|
Bertheau, Philippe
|
|
2013
|
22 |
S2 |
p. S27-S29
3 p.
|
artikel
|
| 29 |
Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors
|
Ingle, James N.
|
|
2013
|
22 |
S2 |
p. S180-S183
4 p.
|
artikel
|
| 30 |
Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis
|
Kerbel, Robert S.
|
|
2013
|
22 |
S2 |
p. S57-S65
9 p.
|
artikel
|
| 31 |
Quantification of residual risk of relapse in breast cancer patients optimally treated
|
Dieci, Maria Vittoria
|
|
2013
|
22 |
S2 |
p. S92-S95
4 p.
|
artikel
|
| 32 |
Selecting the neoadjuvant treatment by molecular subtype: How to maximize the benefit?
|
von Minckwitz, Gunter
|
|
2013
|
22 |
S2 |
p. S149-S151
3 p.
|
artikel
|
| 33 |
Sex hormones and breast cancer risk and prognosis
|
Folkerd, Elizabeth
|
|
2013
|
22 |
S2 |
p. S38-S43
6 p.
|
artikel
|
| 34 |
The continued evidence from overviews: What is the clinical utility?
|
Turner, Natalie
|
|
2013
|
22 |
S2 |
p. S8-S11
4 p.
|
artikel
|
| 35 |
The metastatic microenvironment of breast cancer: Clinical implications
|
Coleman, R.E.
|
|
2013
|
22 |
S2 |
p. S50-S56
7 p.
|
artikel
|
| 36 |
Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies
|
Pinto, Ana Catarina
|
|
2013
|
22 |
S2 |
p. S152-S155
4 p.
|
artikel
|
| 37 |
Who should not undergo breast conservation?
|
Nijenhuis, Matthijs V.
|
|
2013
|
22 |
S2 |
p. S110-S114
5 p.
|
artikel
|
Tijdschrift beschrijving